Breaking World Pharma News

Leaps by Bayer leads $80M Series A financing for Cellino Biotech to autonomize stem cell therapy manufacturing

Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, today announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG - Leaps by Bayer - 8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining existing investors The Engine and Khosla Ventures. The company has raised a total of $96 million in gross proceeds from private financings to date.

New study suggests two paths toward ‘super immunity’ to COVID-19

New laboratory research from Oregon Health & Science University reveals more than one path toward robust immunity from COVID-19.

A new study finds that two forms of immunity - breakthrough infections following vaccination or natural infection followed by vaccination - provide roughly equal levels of enhanced immune protection.

Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies demonstrating that three doses of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) elicited antibodies that neutralize the Omicron variant (B.1.1.529).

SMi Group's 13th Annual Conference: RNA Therapeutics 2022

9 - 10 February 2022, Virtual Conference.
The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry's leading role in developing vaccines against COVID-19 in response to the global pandemic. This year's conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development.

The cellular response that protects pigs from COVID-19

Iowa State University scientists may have uncovered an important clue that sheds light on why pigs don’t get sick when exposed to the coronavirus.

Studies since the start of the pandemic have noted that pigs can be infected by the virus if exposed to high doses, but the infection is self-limited and pigs don’t show clinical signs of disease nor do they transmit the virus to other animals.

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

More than 1.2 million people - and potentially millions more - died in 2019 as a direct result of antibiotic-resistant bacterial infections, according to the most comprehensive estimate to date of the global impact of antimicrobial resistance (AMR).

The analysis of 204 countries and territories, published in The Lancet, reveals that AMR is now a leading cause of death worldwide, higher than HIV/AIDS or malaria.

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-end AI-driven platform utilizing actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia's novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.

Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events

The placebo effect is the well-known phenomenon of a person's physical or mental health improving after taking a treatment with no pharmacological therapeutic benefit - a sugar pill, or a syringe full of saline, for example. While the exact biological, psychological and genetic underpinnings of the placebo effect are not well understood, some theories point to expectations as the primary cause and others argue that non-conscious factors embedded in the patient-physician relationship automatically turn down the volume of symptoms.

Pfizer shares in vitro efficacy of novel COVID-19 oral treatment against omicron variant

Pfizer Inc. (NYSE: PFE) today shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron. Taken together, these in vitro studies suggest that PAXLOVID has the potential to maintain plasma concentrations many-fold times higher than the amount required to prevent Omicron from replicating in cells.

SMi's 5th Annual 3D Cell Culture Conference

9 - 10 February 2022, Virtual Conference: Online Access Only.
3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery, from improved clinical translation and predictivity, to patient safety and sustainability.

WORLDPHARMANEWS

Breaking World Pharma News

Leaps by Bayer leads $80M Series A financing for Cellino Biotech to autonomize stem cell therapy manufacturing

New study suggests two paths toward ‘super immunity’ to COVID-19

Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant

SMi Group's 13th Annual Conference: RNA Therapeutics 2022

The cellular response that protects pigs from COVID-19

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events

Pfizer shares in vitro efficacy of novel COVID-19 oral treatment against omicron variant

SMi's 5th Annual 3D Cell Culture Conference

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs